CN104306379A - Externally applied pharmaceutical preparation for treating skin superficial fungal infections - Google Patents
Externally applied pharmaceutical preparation for treating skin superficial fungal infections Download PDFInfo
- Publication number
- CN104306379A CN104306379A CN201410526917.5A CN201410526917A CN104306379A CN 104306379 A CN104306379 A CN 104306379A CN 201410526917 A CN201410526917 A CN 201410526917A CN 104306379 A CN104306379 A CN 104306379A
- Authority
- CN
- China
- Prior art keywords
- tinea
- superficial
- skin
- carbonyl
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031888 Mycoses Diseases 0.000 title abstract description 12
- 206010017533 Fungal infection Diseases 0.000 title abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 38
- 239000002253 acid Substances 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 241000233866 Fungi Species 0.000 claims description 17
- 208000002474 Tinea Diseases 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 8
- 206010005913 Body tinea Diseases 0.000 claims description 4
- 201000010618 Tinea cruris Diseases 0.000 claims description 4
- 206010067197 Tinea manuum Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 201000003875 tinea corporis Diseases 0.000 claims description 4
- 201000004647 tinea pedis Diseases 0.000 claims description 4
- 208000007712 Tinea Versicolor Diseases 0.000 claims description 3
- 206010043866 Tinea capitis Diseases 0.000 claims description 3
- 206010056131 Tinea versicolour Diseases 0.000 claims description 3
- 241000223238 Trichophyton Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000004568 cement Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 8
- 241000130764 Tinea Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 239000002002 slurry Substances 0.000 description 6
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 5
- 229960004022 clotrimazole Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003813 thumb Anatomy 0.000 description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 244000036770 Akebia trifoliata Species 0.000 description 2
- 235000012980 Akebia trifoliata Nutrition 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004362 fungal culture Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241000722953 Akebia Species 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 208000031868 Calculus ureteric Diseases 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940122069 Glycosidase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010048625 Skin maceration Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an externally applied pharmaceutical preparation for treating skin superficial fungal infections. The pharmaceutical preparation is prepared from an active ingredient and additives, wherein the active ingredient comprises 2-hydroxy-3-carbonyl-23-norolean-1, 4, 12-triene-28-acid or a derivative thereof. The invention provides a medicine prepared from 2-hydroxy-3-carbonyl-23-norolean-1, 4, 12-triene-28-acid or the derivative thereof for treating the skin superficial fungal infections, and the medicine has a good treatment effect and low recurrence rate.
Description
Technical field
The invention belongs to dermatosis treating medicine preparation technique field, in particular to a kind of external medicine preparation for the treatment of superficial fungous infection of skin.
Background technology
The tinea such as the tinea manuum caused by superficial fungous infection of skin, tinea pedis, tinea corporis, tinea cruris are a kind of dermatosiss of superficial fungal infection of obstinate refractory, and show as water kitchen, keratinization and scaling patch, Main Pathogenic Bacteria is alpha fungus, trichophyton etc.-as can be divided into immersion-type, vesicle and squama keratinization type three kinds.Immersion-type-as referring to skin maceration between toe, turning white, rubbing with the hands and remove epidermis, expose red rotten to the corn face, easy secondary infection; Vesicle is often the large phlysis of syringe needle, sometimes can be fused into bulla; Squama keratinization type thickens based on desquamation, boundary clear, has vesicle.Tinea, according to suffering from the difference at tinea position, includes tinea capitis, the tinea manuum, tinea pedis, tinea corporis, tinea cruris, tinea versicolor etc., all can pruritus unbearably, more, the course of disease is slow for Changzhi difficulty, and after treatment, relapse rate is high.
Causing the fungus of tinea to have extremely strong vitality and cross infection characteristic, is one of current dermatosis more rambunctious.If tinea patient does not adhere to using Drug therapy, fungus is not thoroughly killed, after a while will amount reproduction again, and cause " recurrence ", so obstinate refractory, thus tinea Changzhi is difficult heals.Need to find the higher pharmaceutical preparation of curative effect, improve tinea cure rate, reduce relapse rate.
Olive-1 falls in native compound 2-hydroxyl-3-carbonyl-23-, 4, 12-triolefin-28-acid is from Caulis Akebiae (Akebia quinata (Thumb.) Decne.), threeleaf akebia (Akebiatrifolia (Thumb.) Koidz), long sequence Caulis Akebiae (Akebia longeracemosaMatsumura), the stem of Caulis Akebiae (Akebiatrifolia (Thumb.) Koidz.Var.australis (Diels) Rehd) or long calyx threeleaf akebia (Akebiatrifolia (Thumb.) Koidz..subsp.LongisepalaH.N.Qin), in leaf or fruit, preparative separation obtains.CN103739653A discloses one and comprises 2-hydroxyl-3-carbonyl-23-and fall olive-Isosorbide-5-Nitrae, and 12-triolefin-28-acid falls oleanane acid compound and preparation method thereof at interior 23-, and discloses this compound and preparing the purposes in glycosidase inhibitor.By retrieval domestic and foreign literature, still do not find that olive-Isosorbide-5-Nitrae falls in 2-hydroxyl-3-carbonyl-23-, 12-triolefin-28-acid has the bioactive bibliographical information of anti-fungal infection.
Summary of the invention
The object of the present inventor is by studying natural drug, provides a kind of external medicine preparation for the treatment of superficial fungous infection of skin.This pharmaceutical preparation falls olive-1 with 2-hydroxyl-3-carbonyl-23-, 4,12-triolefin-28-acid or derivatives thereof is active component, has therapeutical effect very preferably, can be developed into the external medicine preparation for the treatment of superficial fungous infection of skin to the animal model of the fungal infection such as alpha fungus.
In order to realize object of the present invention, inventor is studied and persistent exploration by a large amount of animal experiment, finally obtains following technical scheme:
Treat an external medicine preparation for superficial fungous infection of skin, this pharmaceutical preparation is prepared from by active component and adjuvant, and described active component comprises 2-hydroxyl-3-carbonyl-23-and falls olive-Isosorbide-5-Nitrae, 12-triolefin-28-acid or derivatives thereof.The structural formula of this compound is as follows:
It should be noted that, olive-1 falls in described 2-hydroxyl-3-carbonyl-23-, 4, the derivant of 12-triolefin-28-acid is that olive-1 falls in 2-hydroxyl-3-carbonyl-23-, one or two derivant obtained with organic acid or Organic Alcohol esterification respectively in the 2-position hydroxyl of 4,12-triolefin-28-acid and 28-position carboxyl functional group.
In addition, in embodiment preferred for this invention, the active component for the treatment of as mentioned above in the external medicine preparation of superficial fungous infection of skin falls olive-Isosorbide-5-Nitrae by 2-hydroxyl-3-carbonyl-23-, and 12-triolefin-28-acid is prepared from as sole component.
The external medicine preparation for the treatment of superficial fungous infection of skin of the present invention, its dosage form can be the multiple exterior-applied formulations such as ointment, ointment, liniment, spray, membrane.These dosage forms all fall olive-Isosorbide-5-Nitrae with 2-hydroxyl-3-carbonyl-23-, and 12-triolefin-28-acid or derivatives thereof, as active component, is the common process that those skilled in the art utilize this area, the basis not spending creative work can be prepared from.Especially, external membrane of the present invention can adopt following processing step to prepare:
(1) take 15-25 part polyvinyl alcohol, 5-10 part sodium carboxymethyl cellulose respectively adds moistening in purified water respectively, stir, soak 36h, make it fully swelling, again to 75-98 DEG C of heating in water bath to dissolving, obtain polyvinyl alcohol glue serosity and sodium carboxymethyl cellulose rubber cement liquid respectively, for subsequent use;
(2) take 1 part of 2-hydroxyl-3-carbonyl-23-and fall olive-1,4,12-triolefin-28-acid is put in mortar, adds 3-5 part azone successively, 3-5 part tween 80,1.5-3 part glycerol, and the polyvinyl alcohol glue serosity prepared of step (1) and sodium carboxymethyl cellulose rubber cement liquid, limit edged grinds, even to grinding, put 55-65 DEG C of water bath heat preservation 0.3-1.0h again, after sloughing bubble, obtain medicine film slurry;
(3) incline on sterile glass plate by medicine film slurry, evenly, put oven drying, after film forming, demoulding, all cuts, sterilizing, aseptic packaging in tiling.
Mycotic infection of superficial part model is dermatophytosis model mainly, and tinea animal model generally infects Cavia porcellus with alpha fungus, and often select " skin trauma infection method ", observation index is mainly the lesion degree of focus.The present inventor is studied the anti-superficial fungal infection drug action of prepared pharmaceutical preparation by this animal model, result shows this medicine can make the skin lesion of model guinea pigs disappear, continuous 2 feminine genders of fungus microscope examination and fungal culture feminine gender, prove that convection potential Cavia porcellus alpha fungus infection model has good curative effect.Therefore, the present invention also provides a kind of pharmaceutical applications, that is: olive-Isosorbide-5-Nitrae falls in 2-hydroxyl-3-carbonyl-23-, the application of 12-triolefin-28-acid or derivatives thereof in the external used medicine of preparation treatment superficial fungous infection of skin.Preferably, described superficial fungi comprises alpha fungus or/and trichophyton.Further preferably, described superficial fungous infection of skin comprises any one of tinea capitis, the tinea manuum, tinea pedis, tinea corporis, tinea cruris and tinea versicolor.
Compared with prior art, the invention provides 2-hydroxyl-3-carbonyl-23-and fall olive-Isosorbide-5-Nitrae, 12-triolefin-28-acid and derivant thereof are for the preparation of the medicine for the treatment of superficial fungous infection of skin, this medication effect is good, relapse rate is low, and in drug withdrawal, after 4 weeks, it does not occur relapse indications, for bringing the drug candidate of new this disease for the treatment of clinically, and this compound is as natural product abundance, therefore save medical expense, alleviate patient economy burden, have larger clinical value.
Detailed description of the invention
Be below preparation embodiment and the effect test example of external medicine preparation of the present invention, the description of these embodiments can understand and apply the invention for ease of those skilled in the art.Person skilled in the art obviously easily can make various amendment to these embodiments, and General Principle described herein is applied in other embodiments and need not through performing creative labour.Therefore, protection scope of the present invention is not limited to these embodiments, and those skilled in the art, according to announcement of the present invention, do not depart from improvement that scope makes and amendment all should within protection scope of the present invention.
the preparation of embodiment 1 external membrane
(1) take 10g PVA, 4g sodium carboxymethyl cellulose and respectively add purified water 30,40ml moistening respectively, stir, soak 36h, make it fully swelling, again to 90 DEG C heating in water bath, to dissolving, obtains PVA rubber cement liquid and sodium carboxymethyl cellulose rubber cement liquid respectively, for subsequent use.
(2) take 0.5g 2-hydroxyl-3-carbonyl-23-and fall olive-1,4,12-triolefin-28-acid is put in mortar, adds 2g azone successively, 2g tween 80,1g glycerol, and the PVA rubber cement liquid prepared of step (1) and sodium carboxymethyl cellulose rubber cement liquid, limit edged grinds, even to grinding, put 60 DEG C of water bath heat preservation 30min again, after sloughing bubble, obtain medicine film slurry.
(3) incline on sterile glass plate by medicine film slurry, evenly, put baking oven 65 DEG C of dryings, after film forming, demoulding, is all slit into 6cm × 8cm fritter, totally 8 pieces in tiling, indoor in sterile working, with ultra violet lamp medicine film 15min sterilizing, is packaged in sterile bag.
the preparation of embodiment 2 external membrane
(1) take 30g PVA, 10g sodium carboxymethyl cellulose respectively adds purified water 100ml moistening respectively, stir, soak 48h, make it fully swelling, again to 90 DEG C heating in water bath, to dissolving, obtains PVA rubber cement liquid and sodium carboxymethyl cellulose rubber cement liquid respectively, for subsequent use.
(2) take 1g 2-hydroxyl-3-carbonyl-23-and fall olive-1,4,12-triolefin-28-acid is put in mortar, adds 5g azone successively, 5g tween 80,3g glycerol, and the PVA rubber cement liquid prepared of step (1) and sodium carboxymethyl cellulose rubber cement liquid, limit edged grinds, even to grinding, put 60 DEG C of water bath heat preservation 30min again, after sloughing bubble, obtain medicine film slurry.
(3) incline on sterile glass plate by medicine film slurry, evenly, put baking oven 65 DEG C of dryings, after film forming, demoulding, is all slit into 6cm × 8cm fritter, totally 20 pieces in tiling, indoor in sterile working, with ultra violet lamp medicine film 15min sterilizing, is packaged in sterile bag.
the preparation of the blank membrane of comparative example 1 external
Fall olive-Isosorbide-5-Nitrae except not adding 2-hydroxyl-3-carbonyl-23-in step 2,12-triolefin-28-acid, other steps and supplementary product kind and consumption are all with embodiment 2.
embodiment 3 medicine infects the therapeutic test research of guinea pig model to alpha fungus
Choose alpha fungus (
trichophyton mentagrophytes) ATCC4439 is as pathogenic bacterium, recover its pathogenicity before experiment and be inoculated in husky fort agar (SDA) slant tube, 26 DEG C of cultivations, after 7 ~ 10d, careful scraping bacterium colony, makes fungal infection suspension with normal saline for subsequent use.SDA is made up of 4% glucose, 1% peptone and 2% agar.
Healthy albino guinea-pig 36, male and female dual-purpose, body weight 250 ~ 350g.The becoming mildewed of abdomen back of all albino guinea-pigs is cut short, then slough hair with razor and make 8cm × 10cm unhairing district, and be coated with qs glycerin in case chapped skin in depilation district, repeatedly to rub unhairing district skin with sand paper again, damage surface is about 3cm × 5cm, transudate is had but massive hemorrhage is not as the criterion with skin, the alpha fungus suspension of preparation is embrocated in injured skin, after fungal infection, in the 10th day, observe the lesion degree of the infected area skin of albino guinea-pig, scraping erythra, squama or crust, the mycelia of microscopic examination fungus or spore.Prove that frosted traumatic infection method infects Infection Model in Guinea Pig success.
After alpha fungus infection Infection Model in Guinea Pig is made, the animal pattern of infection is divided into following three groups at random, be respectively clotrimazole cream group and (use clotrimazole cream, the accurate word H50020636 of traditional Chinese medicines, specification 10g:3%), test group (use the embodiment of the present invention 2 prepare external membrane) and blank group (using the external blank membrane of above-mentioned comparative example 1 preparation), often organize 12, male and female half and half.Give corresponding medicine respectively for each group, every day, application medical adhesive tape fixed medicine film in disease damage place medication 1 time, after administration 4d, observed every day and checked curative effect, and the rehabilitation recovery from illness situations such as record lesion erythra, squama or crust, until 14d.Cure as skin lesion disappears, continuous 2 feminine genders of fungus microscope examination and fungal culture feminine gender; Invalidly do not disappear for skin lesion, fungus microscope examination is positive.Record the recovery from illness number of each treated animal and calculate cure rate.Stop the recurrence that observation post administration cures animal.
Each group of difference administration clotrimazole cream, medicine for external use film and blank medicine film, continuous Ureteral Calculus 14d, wherein checks 7, l0, and the cure rate of 14 d is as shown in table 1.As can be seen from the test statistics result of table 1, test group evident in efficacy, and be better than positive control medicine clotrimazole cream, this imply that and fall olive-1 with 2-hydroxyl-3-carbonyl-23-, 4,12-triolefin-28-acid is that the external preparation convection potential Cavia porcellus alpha fungus infection model of active fraction preparation has good curative effect.
Table 1: each group alpha fungus infects the comparitive study of Cavia porcellus.
| Group | n | 7d cure rate (%) | 10d cure rate (%) | 14d cure rate (%) | Relapse rate (%) after 4 weeks |
| Blank group | 12 | 0 | 0 | 0 | 0 |
| Clotrimazole cream group | 12 | 0 | 25 | 56.9 | 42.9 |
| Test group | 12 | 58.3 | 91.7 | 100 | 0 |
Visible by upper table, the effect of test group is very outstanding, and curative effect is obvious.
Claims (6)
1. treat the external medicine preparation of superficial fungous infection of skin for one kind, it is characterized in that, described external medicine preparation is prepared from by active component and adjuvant, and described active component comprises 2-hydroxyl-3-carbonyl-23-and falls olive-1,4,12-triolefin-28-acid or derivatives thereof.
2. treat the external medicine preparation of superficial fungous infection of skin according to claim 1, it is characterized in that, described active component falls olive-Isosorbide-5-Nitrae by 2-hydroxyl-3-carbonyl-23-, and 12-triolefin-28-acid forms as sole component.
3. treat the external medicine preparation of superficial fungous infection of skin according to claim 1, it is characterized in that, described external medicine preparation comprises ointment, ointment, liniment, spray and membrane.
Olive-Isosorbide-5-Nitrae falls in 4.2-hydroxyl-3-carbonyl-23-, the application of 12-triolefin-28-acid or derivatives thereof in the external used medicine of preparation treatment superficial fungous infection of skin.
5. application according to claim 4, is characterized in that, described superficial fungi comprises alpha fungus or/and trichophyton.
6. application according to claim 4, is characterized in that, described superficial fungous infection of skin comprises any one of tinea capitis, the tinea manuum, tinea pedis, tinea corporis, tinea cruris and tinea versicolor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410526917.5A CN104306379B (en) | 2014-10-09 | 2014-10-09 | A kind of external medicine preparation treating superficial fungous infection of skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410526917.5A CN104306379B (en) | 2014-10-09 | 2014-10-09 | A kind of external medicine preparation treating superficial fungous infection of skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104306379A true CN104306379A (en) | 2015-01-28 |
| CN104306379B CN104306379B (en) | 2016-08-24 |
Family
ID=52361791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410526917.5A Expired - Fee Related CN104306379B (en) | 2014-10-09 | 2014-10-09 | A kind of external medicine preparation treating superficial fungous infection of skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306379B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739653A (en) * | 2013-12-26 | 2014-04-23 | 中国科学院华南植物园 | Novel 23-oleanolic acid compound as well as preparation method and application of compound in preparation of glycosidase inhibitor medicine |
-
2014
- 2014-10-09 CN CN201410526917.5A patent/CN104306379B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739653A (en) * | 2013-12-26 | 2014-04-23 | 中国科学院华南植物园 | Novel 23-oleanolic acid compound as well as preparation method and application of compound in preparation of glycosidase inhibitor medicine |
Non-Patent Citations (4)
| Title |
|---|
| 刘平等: "木通的选择使用", 《中国医药导报》 * |
| 谢小霞等: "三叶木通药学研究现状与展望", 《现代医药卫生》 * |
| 金继曙等: "油茶籽饼抗真菌活性成分的研究", 《天然产物研究与开发》 * |
| 高亚玲等: "预知子的化学成分、药理作用与临床应用研究", 《河北化工》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104306379B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108524601B (en) | Vaginal gel containing pleiotropic factors and preparation method thereof | |
| CN101862351B (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| CN105168385B (en) | A kind of pharmaceutical composition of anti-bacterial, anti-itching and preparation method thereof | |
| CN105998171B (en) | Application of gentiana macrophylla and extract thereof in preparing medicine for treating and/or preventing skin tinea | |
| CN105395593A (en) | Itching relieving ointment containing folium artemisiae argyi extract and preparation method thereof | |
| CN110755456A (en) | Antifungal medicine composition consisting of American cockroach extract and antifungal medicine | |
| CN104306379B (en) | A kind of external medicine preparation treating superficial fungous infection of skin | |
| WO2024011868A1 (en) | Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis | |
| CN110693895A (en) | Pharmaceutical composition for treating hemorrhoids and preparation thereof | |
| CN102743432B (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN100434083C (en) | Medicinal use of fugu cod liver oil | |
| CN105194330A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
| CN108653247A (en) | It is a kind of to have the defervescence plaster used preparation method for absorbing effect of bringing down a fever | |
| CN108403570A (en) | There are the body condensation and preparation method of improvement to pruitus caused by eczema | |
| CN104707040B (en) | Cypress gruel disappears vaginal plug and preparation method thereof | |
| Carney | Inflammatory Ringworm Due to Trichophyton Faviforme: Report of Seventeen Cases | |
| CN107485655B (en) | Application of peach blossom extract in preparation of medicine for treating prostatitis | |
| CN104083406A (en) | Compound disinfectant and preparation method thereof | |
| CN105168625B (en) | A kind of clinical care is used for the treatment of the Chinese medicine liniment of two, three phase decubital ulcers | |
| CN104840836B (en) | A kind of cypress gruel that treating gynaecologic vaginal inflammation disappears spray and preparation method thereof | |
| CN103860567A (en) | External drug for treating skin diseases and preparation method thereof | |
| CN104606598B (en) | Cypress gruel elimination detergent and preparation method thereof | |
| CN103751230A (en) | Application of gingko extract nanometer liposome in gynecological disease treatment | |
| CN102641277A (en) | Ointment for treating gynaopathy and dermatoses and preparation method thereof | |
| CN103751231A (en) | Application of gingko extract nanometer liposome in acne removing and dermatosis treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181105 Address after: 330010 Room B, Room 2, 1805, Office Building, Xinchen Building, 917 Century, Fenglinxi Street, Nanchang Economic and Technological Development Zone, Nanchang City, Jiangxi Province Patentee after: Nanchang Fu Rui Biotechnology Co., Ltd. Address before: 241000 Department of Dermatology, Wuhu Second People's Hospital, 263 Jiuhua Middle Road, Jinghu District, Wuhu, Anhui Patentee before: Li Jian |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20191009 |